16th Oct 2007 07:00
Henderson Morley PLC16 October 2007 16th October 2007 HENDERSON MORLEY PLC (AIM) Business: Drug Discovery Feline Herpes Virus Update The Board of Henderson Morley plc ("Henderson Morley" or "the Company"), the AIMlisted drug discovery company, is pleased to update the market with progressregarding its treatment of Feline Herpes Virus (FHV) conjunctivitis. The Company is continuing a clinical trial to examine the safety and efficacy ofICVT ophthalmic drops. This study is now underway in Germany, and severalveterinary centres have been recruited. On 20 June 2007, the Company announced the engagement of a specialist veterinaryproduct development consultancy group. This company, Triveritas, is a globalleader in conducting regulatory compliant studies for animal health products andrecently won a worldwide award for Best Supporting Role at the prestigiousAnimal Pharm Industry Excellence Awards 2007. Since this time significantprogress has been made which includes: • Finalisation of the study design and clinical trial protocol • Obtaining ethics committee approval for study conduct • Potential investigators and monitors identified, recruited and trained • Reporting and sampling methods determined • Laboratory methodology developed and validated • Study files created • Quality Audit completed The study is fully VICH GCP compliant and focuses on animals that are alreadynaturally infected by FHV. The treatment regimen involves the administration ofeye drops by the pet owner or veterinary health care professionals. With thefirst patients due to be treated within the next two weeks, results of the studyare anticipated to be on target for the end of Q1 08. Feline herpes virus infections are very common, and represent a major cause ofmorbidity in animal care institutions, the wild feline population and domesticcats, especially at times of breeding. Julian Braidwood, Managing Director of Triveritas, explained "As there arecurrently no authorised treatments available for veterinarians to treat thisdisease, this innovative approach from Henderson Morley could be a great boostfor animal welfare." Executive Chairman Andrew Knight said: "We are pleased with the continuedprogress of the clinical trial and look forward to further updating the marketin due course." --END-- Enquiries: HENDERSON MORLEY PLC Tel: 0121 442 4600Andrew Knight, Chairman BISHOPSGATE COMMUNICATIONS LTD Tel: 020 7562 3350Maxine BarnesNick Rome BREWIN DOLPHIN LTD Tel: 0113 241 0126Neil Baldwin Further information on Henderson Morley plc can be accessed through theCompany's website at www.henderson-morley.com Notes for editors Henderson MorleyHenderson Morley was founded in 1996 with the objective of developing its anti-viral application (Ionic Contra Viral Therapy (ICVT). ICVT is the Lead Platformand has been developed in-house and Henderson Morley wholly owns the patent IPR. Triveritas Triveritas is a dynamic international product development consultancy thatprovides SMEs to multi-national animal health companies with the externalproduct development support they need. Triveritas has offices in the UK, Germanyand France, plus a network of specialist consultants. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
HML.L